NAD+ and Exercise in FA

NAActive, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 3, 2020

Primary Completion Date

February 7, 2025

Study Completion Date

February 7, 2026

Conditions
Friedreich Ataxia 1
Interventions
DIETARY_SUPPLEMENT

Nicotinamide Riboside

"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."

DIETARY_SUPPLEMENT

Placebo

The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule).

OTHER

Exercise Intervention

"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands.~On aerobic training days, subjects will be given instruction on a recumbent Catrike trainer, titrated such that they spend 20 minutes at their target heart rate as determined by baseline Exercise Stress Test (EST) (60-80% of their heart rate at peak VO2) and as measured by their wearable device.~On resistance training days, subjects will be given instructions to complete circuits of resistance exercises. Resistance training intensity (as determined by graded resistance bands) will be maintained at 60% of pre-training maximal voluntary contraction for each muscle group."

Trial Locations (1)

19104

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Children's Hospital of Philadelphia

OTHER